Look­ing to ex­pand Pyrukynd la­bel, Agios treks to­ward PhI­II in sick­le cell dis­ease

Agios Phar­ma­ceu­ti­cals said Mon­day that its pill Pyrukynd in­creased lev­els of he­mo­glo­bin in more sick­le cell dis­ease pa­tients than place­bo, and it plans to start a Phase III tri­al lat­er this year.

Pyrukynd is al­ready ap­proved for a rare ge­net­ic dis­ease known as pyru­vate ki­nase de­fi­cien­cy, and Agios is look­ing to ex­pand its la­bel in­to more preva­lent blood dis­eases, such as sick­le cell dis­ease and tha­lassemia.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER